| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) | National Cancer Institute (NCI) | 2018-06-05 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (NCT03210714) | National Cancer Institute (NCI) | 2018-06-05 |
| ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (NCT02917629) | National Cancer Institute (NCI) | 2018-05-31 |
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (NCT03030378) | National Cancer Institute (NCI) | 2018-05-30 |
| Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers (NCT03345784) | National Cancer Institute (NCI) | 2018-05-29 |
| Questionnaire Pre-Test Study (NCT03248635) | National Cancer Institute (NCI) | 2018-05-25 |
| Biospecimen Procurement for Head and Neck Disorders (NCT03429036) | National Cancer Institute (NCI) | 2018-05-23 |
| Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients (NCT02706652) | National Cancer Institute (NCI) | 2018-05-22 |
| Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer (NCT03382561) | National Cancer Institute (NCI) | 2018-05-21 |
| Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer (NCT03480152) | National Cancer Institute (NCI) | 2018-05-18 |
| M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas (NCT03451773) | National Cancer Institute (NCI) | 2018-05-17 |
| Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (NCT03468985) | National Cancer Institute (NCI) | 2018-05-07 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (NCT03493945) | National Cancer Institute (NCI) | 2018-05-01 |
| Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas (NCT03258567) | National Cancer Institute (NCI) | 2018-04-26 |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149) | National Cancer Institute (NCI) | 2018-04-25 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery (NCT03190967) | National Cancer Institute (NCI) | 2018-04-18 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652) | National Cancer Institute (NCI) | 2018-04-17 |
| Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer (NCT03367741) | National Cancer Institute (NCI) | 2018-04-16 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas (NCT03233724) | National Cancer Institute (NCI) | 2018-04-11 |
| Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer (NCT03300843) | National Cancer Institute (NCI) | 2018-04-11 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT03258554) | National Cancer Institute (NCI) | 2018-04-03 |
| Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer (NCT02899728) | National Cancer Institute (NCI) | 2018-03-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors (NCT03366103) | National Cancer Institute (NCI) | 2018-03-20 |
| Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (NCT03315871) | National Cancer Institute (NCI) | 2018-03-20 |
| Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (NCT02876640) | National Cancer Institute (NCI) | 2018-03-16 |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction (NCT03217253) | National Cancer Institute (NCI) | 2018-03-16 |
| Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (NCT03220022) | National Cancer Institute (NCI) | 2018-03-16 |
| Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging (NCT03027466) | National Cancer Institute (NCI) | 2018-03-06 |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma (NCT03436732) | National Cancer Institute (NCI) | 2018-02-28 |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (NCT06385483) | National Cancer Institute (NCI) | 2018-02-28 |
| M7824 in Subjects With HPV Associated Malignancies (NCT03427411) | National Cancer Institute (NCI) | 2018-02-27 |
| Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer (NCT03354416) | National Cancer Institute (NCI) | 2018-02-26 |
| Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers (NCT03402230) | National Cancer Institute (NCI) | 2018-02-20 |
| Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas (NCT03255018) | National Cancer Institute (NCI) | 2018-02-15 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (NCT03223610) | National Cancer Institute (NCI) | 2018-02-09 |
| Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688) | National Cancer Institute (NCI) | 2018-02-08 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer (NCT03201458) | National Cancer Institute (NCI) | 2018-02-08 |
| Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (NCT03008278) | National Cancer Institute (NCI) | 2018-02-06 |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (NCT03388632) | National Cancer Institute (NCI) | 2018-02-05 |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT03092674) | National Cancer Institute (NCI) | 2018-02-02 |
| Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer (NCT03384316) | National Cancer Institute (NCI) | 2018-01-31 |
| Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy (NCT03407040) | National Cancer Institute (NCI) | 2018-01-30 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (NCT03269669) | National Cancer Institute (NCI) | 2018-01-23 |
| Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (NCT02997228) | National Cancer Institute (NCI) | 2018-01-19 |
| Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy (NCT03388619) | National Cancer Institute (NCI) | 2018-01-17 |
| ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma (NCT03394027) | National Cancer Institute (NCI) | 2018-01-17 |
| Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (NCT02965703) | National Cancer Institute (NCI) | 2018-01-16 |
| Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions (NCT03197025) | National Cancer Institute (NCI) | 2018-01-09 |
| MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (NCT03300817) | National Cancer Institute (NCI) | 2017-12-27 |
| Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease (NCT03300830) | National Cancer Institute (NCI) | 2017-12-20 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma (NCT03063632) | National Cancer Institute (NCI) | 2017-12-14 |
| A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer (NCT03206073) | National Cancer Institute (NCI) | 2017-12-07 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (NCT02974621) | National Cancer Institute (NCI) | 2017-12-07 |
| Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (NCT03180034) | National Cancer Institute (NCI) | 2017-11-29 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer (NCT03300557) | National Cancer Institute (NCI) | 2017-11-15 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035) | National Cancer Institute (NCI) | 2017-11-08 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03206047) | National Cancer Institute (NCI) | 2017-11-08 |
| Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (NCT03244384) | National Cancer Institute (NCI) | 2017-11-03 |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (NCT03220009) | National Cancer Institute (NCI) | 2017-11-03 |
| Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy (NCT03223662) | National Cancer Institute (NCI) | 2017-10-31 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03213691) | National Cancer Institute (NCI) | 2017-10-30 |
| Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer (NCT02961374) | National Cancer Institute (NCI) | 2017-10-27 |
| Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer (NCT03327883) | National Cancer Institute (NCI) | 2017-10-26 |
| Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (NCT02879695) | National Cancer Institute (NCI) | 2017-10-25 |
| Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma (NCT03033576) | National Cancer Institute (NCI) | 2017-10-23 |
| Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559) | National Cancer Institute (NCI) | 2017-10-16 |
| Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer (NCT03018249) | National Cancer Institute (NCI) | 2017-10-11 |
| Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (NCT03206060) | National Cancer Institute (NCI) | 2017-10-10 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625) | National Cancer Institute (NCI) | 2017-09-27 |
| Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (NCT03018288) | National Cancer Institute (NCI) | 2017-09-21 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03190941) | National Cancer Institute (NCI) | 2017-09-21 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT02890329) | National Cancer Institute (NCI) | 2017-09-05 |
| Sample Collection and Tracking for the Developmental Therapeutics Clinic (NCT03269578) | National Cancer Institute (NCI) | 2017-08-28 |
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma (NCT02839720) | National Cancer Institute (NCI) | 2017-08-26 |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (NCT03047213) | National Cancer Institute (NCI) | 2017-08-24 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) (NCT06390852) | National Cancer Institute (NCI) | 2017-08-21 |
| Rare CNS Tumors Outcomes &Risk (NCT03251989) | National Cancer Institute (NCI) | 2017-08-21 |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer (NCT03165721) | National Cancer Institute (NCI) | 2017-08-16 |
| Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing (NCT03226704) | National Cancer Institute (NCI) | 2017-08-14 |
| Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (NCT02888743) | National Cancer Institute (NCI) | 2017-08-14 |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (NCT02893917) | National Cancer Institute (NCI) | 2017-08-11 |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors (NCT02723864) | National Cancer Institute (NCI) | 2017-08-09 |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer (NCT03181867) | National Cancer Institute (NCI) | 2017-08-03 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer (NCT02883062) | National Cancer Institute (NCI) | 2017-08-02 |
| NCI UNC Project ESCC (NCT03206125) | National Cancer Institute (NCI) | 2017-08-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Clonal Evolution in Follicular Lymphoma (NCT03190928) | National Cancer Institute (NCI) | 2017-07-27 |
| Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations (NCT03040986) | National Cancer Institute (NCI) | 2017-07-21 |
| Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers (NCT03173950) | National Cancer Institute (NCI) | 2017-07-13 |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma (NCT03041701) | National Cancer Institute (NCI) | 2017-07-07 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma (NCT02911142) | National Cancer Institute (NCI) | 2017-07-03 |
| Long-Term Stability of Oral Microbiome Samples (NCT03068546) | National Cancer Institute (NCI) | 2017-06-29 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707) | National Cancer Institute (NCI) | 2017-06-23 |
| Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (NCT03036930) | National Cancer Institute (NCI) | 2017-06-23 |